Understanding intertumoral heterogeneity is vital for the development of personalized medicine. By recognizing that each tumor is unique, researchers and clinicians can tailor therapeutic strategies to the specific characteristics of an individual's cancer. This leads to more effective treatments and potentially better outcomes for patients.
